Helicobacter pylori infection.
Suerbaum
Sebastian
S
Institute of Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.
Michetti
Pierre
P
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000635:transmission; D016480:Helicobacter pylori / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012459:Salicylates / Q000627:therapeutic use; D014774:Virulence / Q000235:genetics
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D012459:Salicylates; C015715:bismuth subsalicylate; C073340:ranitidine bismuth citrate; D011899:Ranitidine; D001729:Bismuth